Home > Haematology > EHA 2019 > Myeloma > Higher levels of treatment satisfaction without compromising efficacy: subcutaneous daratumumab in RRMM

Higher levels of treatment satisfaction without compromising efficacy: subcutaneous daratumumab in RRMM

Conference
EHA 2019
Trial
Phase 3, COLUMBA

Results of a phase 3 study of daratumumab monotherapy administered subcutaneously (SC) compared with intravenous (IV) administration in patients with relapsed/refractory multiple myeloma (RRMM) showed no significant differences in efficacy or pharmacokinetic endpoints [1].

The IV formulation of daratumumab, a monoclonal antibody targeting CD38, has been approved as either monotherapy or in combination with standard-of-care regimens for patients with RRMM, or when combined with bortezomib/melphalan/dexamethasone for transplant-ineligible, newly diagnosed patients with MM. However, IV daratumumab is typically infused over hours and is associated with infusion reactions in a substantial percentage of patients.

In the open-label, multicentre, phase 3 COLUMBA trial, 522 adult patients with RRMM were randomly assigned in a 1:1 ratio to receive an SC formulation of daratumumab, including recombinant ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on